Jenavalve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR).
The Jenavalve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surgical aortic valve replacement. The Trilogy System is also CE-Mark approved for treatment of severe, symptomatic aortic stenosis.
In the US, Jenavalve is actively enrolling patients in the ALIGN-AR Clinical Trial. Please visit www.Discover-AR.com to learn more about the study and to find the nearest clinical trial site to you.
Jenavalve is headquartered in Irvine, California with offices in Leeds, U.K. and Munich, Germany.
The Trilogy Heart Valve System is not for sale in the US and is limited by Federal (or United States) law to investigational use.